ATIVAN (lorazepam) by Bausch + Lomb. Approved for benzodiazepine [epc]. First approved in 1977.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
ATIVAN (lorazepam) is a benzodiazepine approved in 1977 for anxiety and related disorders, administered orally as a tablet. It works by enhancing GABAergic neurotransmission in the central nervous system to reduce anxiety and promote sedation. The drug is commonly used across multiple settings including psychiatric, medical, and surgical contexts.
As an aging small molecule approaching loss of exclusivity, ATIVAN team size is likely stable or contracting; commercial roles focus on generic transition and specialty channel management rather than growth initiatives.
Benzodiazepine
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan
Phase 1 Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects
Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly
A Study of the Effect of LY2216684 on Lorazepam
Efficacy and Safety Study Comparing Lorazepam and Diazepam for Children in the Emergency Department With Seizures (Status 2)
Worked on ATIVAN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ATIVAN offers stable, defensive commercial experience in a mature product space with established market infrastructure and high volume generics. Career growth depends on specialty positioning, branded-generic strategies, and operational excellence rather than new indication launches or market expansion.